Timber Pharmaceuticals Inc

Timber Pharmaceuticals — Technical Presentation (November 2021)

14 slides from Timber Pharmaceuticals's technical presentation, Nov 22, 2021

  1. Slide 1: Building Bridges in Medical Dermatology: Phase 2b CONTROL Study Results

    Building Bridges in Medical Dermatology TMB - 001 Phase 2b CONTROL Study Results Conference Call November 22, 2021 NYSE American: TMBR

  2. Slide 2: Safe Harbor Statement

    NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitut

  3. Slide 3: Strategic Pipeline in Rare Dermatologic Disease

    NYSE American: TMBR Strategic Pipeline in Rare Dermatologic Disease 3

  4. Slide 4: Unmet Need for Congenital Ichthyosis

    NYSE American: TMBR Unmet Need: An efficacious and safe treatment that can be used long term to cover a large body surface area . 4 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally)  Prevalence • X - Linked Ichthyosis

  5. Slide 5: Topical Isotretinoin in CI

    NYSE American: TMBR 5 TMB - 001 Topical Isotretinoin in CI Patented topical formulation minimizing systemic absorption and allowing for chronic treatment  Isotretinoin is well known as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, whe

  6. Slide 6: Phase IIB Design - Scale Severity

    6 1<6($PHULFDQ  70%5 3KDVH,,% 'HVLJQ ² 6FDOH 6HYHULW\ 

  7. Slide 7: Phase IIB Design - Scale Severity

    7 1<6($PHULFDQ  70%5 3KDVH,,% 'HVLJQ ² 6FDOH 6HYHULW\ 

  8. Slide 8: Investigator's Global Assessment (IGA) Score Point Scale

    NYSE American: TMBR 8 Investigator’s Global Assessment (IGA) Score -- 5 - Point Scale 0 Clear No scaling and no roughness, no fissure 1 Almost Clear Occasional fine scales, hardly palpable roughness (mostly smooth) no fissure 2 Mild Small and fine scales predominate, no more than a few large scales,

  9. Slide 9: Topical Isotretinoin in CI Phase 2B Study Design (CONTROL Study)

    NYSE American: TMBR 9 TMB - 001 Topical Isotretinoin in CI Phase 2B Study Design (CONTROL Study) Title A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB - 001 for Treatment of Congenital Ichthyosis Primary Objective Proportion of subjects with Visual Index of Ichthyosis Sever

  10. Slide 10: CONTROL Study - Efficacy Intent to Treat (ITT)

    NYSE American: TMBR 10 TMB - 001 CONTROL Study - Efficacy Intent to Treat (ITT) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIIS score versus 33% in the vehicle group (nominal p=.17) 55% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versus

  11. Slide 11: CONTROL Study - Efficacy Per Protocol

    NYSE American: TMBR 11 TMB - 001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIIS score versus 40% in the vehicle group (nominal p=.04) 100% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versu

  12. Slide 12: CONTROL Study - Lamellar Ichthyosis Responder Patient

    NYSE American: TMBR 12 TMB - 001 CONTROL Study - 21 yr. old patient with Lamellar Ichthyosis (ALOX12B) - 0.05% arm (responder) End Of Study – Visit 6 Baseline

  13. Slide 13: Significant Clinical Milestones on a Quarterly Basis over next 12 months

    NYSE American: TMBR Significant Clinical Milestones on a Quarterly Basis over next 12 months 13 TMB - 001 TMB - 002 Q4 2021 Topline Data for Phase IIb Trial Completed Enrollment of Phase IIb Q1 2022 End of Phase II FDA Meeting Broad Phase IIb Data Dissemination Q2 2022 Anticipated Start of Phase III

  14. Slide 14: Investor Information Contact

    www.timberpharma.com For additional Investor Information please contact: John Koconis Stephanie Prince Chairman and CEO PCG Advisory jkoconis@timberpharma.com sprince@pcgadvisory.com (646) 863 - 6341 NYSE American: TMBR

Timber Pharmaceuticals — Technical Presentation (November 2021) on 6ix